Savara Inc (NASDAQ: SVRA) had its "market outperform" rating re-affirmed by analysts at JMP Securities. They now have a $8.00 price target on the stock.
Savara to Present New Data on Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the American Thoracic Society (ATS) International Conference 2024 [Yahoo! Finance]
Savara to Present New Data on Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the American Thoracic Society (ATS) International Conference 2024
Savara Announces New Employment Inducement Grant
Savara Reports Fourth Quarter/Year-End 2023 Financial Results and Provides Business Update [Yahoo! Finance]